Patents Examined by Criares
  • Patent number: 6656960
    Abstract: A method for indirectly stimulating a vagus nerve of a patient includes the steps of positioning one or more electrodes in the vicinity of the vagus nerve and then actuating the electrode(s) to create an electrical field for stimulating the vagus nerve. Disclosed embodiments include positioning one or more electrodes in the esophagus, trachea, or jugular vein, on the neck of the patient, and combinations thereof.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: December 2, 2003
    Assignee: Emory University
    Inventor: John D. Puskas
  • Patent number: 6653353
    Abstract: Cosmetic or personal care compositions comprise: a hair styling polymer having one or more groups selected from acidic functional groups, anionic groups derived from the acidic functional groups or a mixture of said groups; a partially or fully fluorinated compound having one or more groups selected from amino groups, acid salts of the amino groups or a mixture of said groups, wherein the partially or fully fluorinated compound comprises an aromatic ring; and a cosmetically acceptable diluent or carrier. The compositions are particularly effective under high humidity conditions.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: November 25, 2003
    Assignee: Unilever Home & Personal Care USA, division of Conopco, Inc.
    Inventors: Gerald Adams, Ezat Khoshdel
  • Patent number: 6653352
    Abstract: A composition containing capsicium extract together with other ingredients to neutralize the discomfort resulting from the application of capsicium extract to the skin enabling treatment of many types of discomforts, including arthritis pain, neuropathy, post surgical scarring, hemorrhoid pain and itching, and pruritis without the discomfort normally associated with the topical application of capsicium extract.
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: November 25, 2003
    Assignee: Medical Merchandising, Inc.
    Inventors: Teresa Leigh Barr, Stephen D. Holt
  • Patent number: 6653350
    Abstract: Methods of treating osteoarthritis by administering an therapeutically effective amount of NOS inhibitor are provided.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: November 25, 2003
    Assignees: G.D. Searle & Co., Pharmacia Corporation
    Inventors: Pamela T. Manning, Jane R. Connor, Mark G. Currie, Jean Pierre Pelletier, Johanne Martel Pelletier
  • Patent number: 6649648
    Abstract: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CO2RC wher
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: November 18, 2003
    Assignee: Novogen Research Pty Limited
    Inventors: Graham Edmund Kelly, George Eustace Joannou
  • Patent number: 6649645
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of radiation therapy and a cyclooxygenase-2 inhibitor.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: November 18, 2003
    Assignee: Pharmacia Corporation
    Inventors: John P McKearn, Jaime L Masferrer, Luka Milas
  • Patent number: 6649617
    Abstract: A method of treating a CNS injury to the brain, in a mammal in need of treatment, which comprises administering to said mammal an effective amount of a cytokine suppressive binding protein compound of formula I wherein the radicals are defined herein.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: November 18, 2003
    Assignee: SmithKline Beecham Corporation
    Inventor: Jerry Leroy Adams
  • Patent number: 6645507
    Abstract: A composition capable of forming a film that ionically bonds to the skin comprising: one or more active agents; a nonionic or substantially nonionic first film forming component; one or more cationic surfactants comprising one or more fatty moieties that are soluble in the first film forming component; and a liquid carrier. Also provided are stable emulsions of such compositions, compositions that are especially adapted to delivering medicinal agents to the surface of the skin, and methods for preparing such compositions.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: November 11, 2003
    Assignee: American Medical Research, Inc.
    Inventors: Griscom Bettle, William S. Coury, Berno I. Pettersson
  • Patent number: 6646008
    Abstract: In accordance with the present invention, it has been discovered that PPAR&ggr; is expressed consistently in tissues associated with each of a variety of disease states which result from neoplastic cell proliferation. It has further been discovered that maximal activation of PPAR&ggr; with exogenous ligand promotes terminal differentiation of primary cells which are otherwise subject to neoplastic cell proliferation. In accordance with another aspect of the invention, it has been discovered that RXR-specific ligands are also potent agents for induction of differentiation of cells expressing the PPAR&ggr;/RXR&agr; heterodimer, and that simultaneous treatment of cells subject to neoplastic cell proliferation with a PPAR&ggr;-selective ligand, in combination with an RXR-specific ligand, results in an additive stimulation of differentiation.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: November 11, 2003
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Peter Tontonoz, Laszlo Nagy
  • Patent number: 6638938
    Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: October 28, 2003
    Assignee: Cell Therapeutics, Inc.
    Inventors: Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
  • Patent number: 6638920
    Abstract: The present invention relates to compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses. The present invention further relates to compositions and methods for alleviating pain associated with skeletal injuries in horses and to treating skeletal injuries in horses.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: October 28, 2003
    Assignee: Merck & Co., Inc.
    Inventor: Donald R. Thompson
  • Patent number: 6635627
    Abstract: The invention concerns a novel approach for treating cystic fibrosis using, in particular, anti-cancer chemotherapy. For the treatment of cystic fibrosis it proposes the use of at least one product which when administered to a patient brings about the expression or overexpression of an ABC carrier compound, in particular glutathione carrier. Preferably, the products used are anti-cancer products whose administration brings about the expression of MRP and/or MDR protein. The invention is also applicable to the treatment of rheumatoid polyarthritis or asthma. More specifically, the compounds are selected among cyclophosphamide, aclarubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, zorubicin, pirabucin, colchicine, videsine, vinorelbine, vincristine, binblasine, azithromycin, erythromycin, ifosmamide, N-acetyl cysteine, N-acetyl lysine and/or a CFTR protein fragment comprising the NBF1 domain.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: October 21, 2003
    Assignee: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Véronique Stoven, Gérard Lenoir, Jean-Yves Lallemand, Jean-Philippe Annereau, Joël Barthe, Sylvain Blanquet
  • Patent number: 6635679
    Abstract: The present invention relates to methods and processes of inactivating a viral contaminants in a biological source material or process intermediate by contacting the biological source material (e.g., a host cell, cell supernatant, cell lysate, blood plasma, tissue homogenate, or other biological materials) with a solution containing one or more alkylamine compounds. In a particular embodiment, the active ingredients are amphipathic, charged amines or amine oxides coupled to saturated hydrocarbon chains of varying lengths.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: October 21, 2003
    Assignee: Akzo Nobel N.V.
    Inventor: Scot R. Shepard
  • Patent number: 6635678
    Abstract: Fecal incontinence and anal itch can be treated by administration, more particularly by local application to the anus, of an a adrenergic blocker, nitric oxide synthase inhibitor, prostaglandin F2&agr;, dopamine, morphine, &bgr;-blockers, and 5-Hydroxytryptamine. The patients who benefit most from the invention are those who have a normal or low maximum anal resting pressure and a structurally intact internal anal sphincter muscle, and patients who have had major bowel resection and reanastomisis.
    Type: Grant
    Filed: August 24, 1999
    Date of Patent: October 21, 2003
    Assignee: S.L.A. Pharma AG
    Inventors: Michael A. Kamm, Robin K. S. Phillips
  • Patent number: 6630477
    Abstract: The present invention relates to (1R,4S)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol and its use in medical therapy for the treatment of hepatitis B infection.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: October 7, 2003
    Assignee: SmithKline Beecham Corporation
    Inventor: Susan Mary Daluge
  • Patent number: 6630502
    Abstract: A method is provided for slowing the progression of atherosclerosis in hypertensive or normotensive patients and reducing or eliminating atherosclerotic lesions in such patients by administering a combination of a cholesterol lowering drug such as pravastatin, and an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril.
    Type: Grant
    Filed: December 2, 1991
    Date of Patent: October 7, 2003
    Assignee: E.R. Squibb & Sons, Inc.
    Inventors: James L. Bergey, Werner Tschollar, Cary S. Yonce, James C. Kawano
  • Patent number: 6630490
    Abstract: A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The disease-induced peripheral neuropathy can be diabetic neuropathy or disease-induced peripheral neuropathy with another basis.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: October 7, 2003
    Assignee: NeoTherapeutics, Inc.
    Inventors: Jack Diamond, Alvin J. Glasky
  • Patent number: 6624195
    Abstract: This invention relates to the treatment of depression by administering a composition of essential fatty acids of eicosapentaenoic (EPA) and steraridonic (SA) acids.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: September 23, 2003
    Assignee: Scotia Holdings PLC.
    Inventor: David Frederick Horrobin
  • Patent number: 6623748
    Abstract: A biocompatible connective tissue repair composition which comprises a therapeutic material and a carrier comprising a means for achieving reverse phase characteristics, and methods for using said composition. The therapeutic material can be demineralized bone powder, and the carrier can be a poloxamer such as poloxamer 407.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: September 23, 2003
    Assignee: Gensci OrthoBiologics, Inc.
    Inventor: Cameron M. L. Clokie
  • Patent number: 6620845
    Abstract: The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives and compositions.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: September 16, 2003
    Assignee: NeuroMolecular, Inc.
    Inventors: Yuqiang Wang, Wenqing Ye, James W. Larrick, Jonathan S. Stemler, Stuart A. Lipton